Wednesday, July 8, 2026

Drug profile · INN

tivozanib

tivozanib (TIVOZANIB) is a vascular endothelial growth factor receptor inhibitor. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — tivozanib
US status
approved
Class
Route
Patents
0
Programs
1
Data quality
0.81

Quick answer

tivozanib (TIVOZANIB) is a vascular endothelial growth factor receptor inhibitor. Current US regulatory status: approved.

Key facts

INN tivozanib
Brand TIVOZANIB
Mechanism Vascular endothelial growth factor receptor inhibitor
Target Vascular endothelial growth factor receptor
Formulation CAPSULE

Mechanism of action

Vascular endothelial growth factor receptor inhibitor

Primary target: Vascular endothelial growth factor receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. AV-951-20-304 Phase 3 · Anaxis Pharma · Renal cell carcinoma

Related & competitor drugs

  1. axitinib Antineoplastic and immunomodulating agents (L01)
  2. fruquintinib Antineoplastic and immunomodulating agents (L01)
  3. lenvatinib mesylate Vascular endothelial growth factor receptor inhibitor
  4. ramucirumab Antineoplastic and immunomodulating agents (L01)
  5. lenvatinib mesilate Vascular endothelial growth factor receptor inhibitor

Frequently asked questions

What is tivozanib?

tivozanib (TIVOZANIB) is a vascular endothelial growth factor receptor inhibitor. Current US regulatory status: approved.

What is the brand name for tivozanib?

TIVOZANIB is a marketed brand name for tivozanib. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tivozanib?

tivozanib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.